Phase 1 study assessing the pharmacokinetics of NEX-22A in subjects with T2D

2023-508054-25-01 Protocol NEX-22-01 Human pharmacology (Phase I) - Other Ended

Start 26 Feb 2025 · End 5 May 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NEX-22-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 12
Countries 1
Sites 1

Type 2 diabetes

Key facts

Sponsor
Nanexa AB
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
26 Feb 2025 → 5 May 2025
Decision date (initial)
2024-05-15
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Type 2 diabetes

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Nanexa AB

Sponsor organisation
Nanexa AB
Address
Virdings Alle 2, Vaksala Vaksala
City
Uppsala
Postcode
754 50
Country
Sweden

Scientific contact point

Organisation
Nanexa AB
Contact name
Head office

Public contact point

Organisation
Nanexa AB
Contact name
Head office

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 12 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
PROFIL Institut fuer Stoffwechselforschung GmbH
n/a, Hellersbergstrasse 9, Hammfeld, Neuss

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-05-27 2025-05-05 2024-05-27 2025-05-05

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-56437

Halt date
2024-11-04
Member states concerned
Germany
Publication date
2024-11-08
Reason
Sponsor decision
Explanation
A substantial modification might be implemented to continue the trial with another cohort. The decision is pending.
Follow-up measures
not applicable
Benefit-risk balance changed
No
Treatment stopped
No

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-05 Germany Acceptable
2024-05-14
2024-05-15
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-09-19 Germany Acceptable
2024-05-14
2024-09-19
3 SUBSTANTIAL MODIFICATION SM-1 2024-12-19 Germany Acceptable
2025-01-24
2025-01-24